{"classes":[{"categories":[{"measurements":[{"comment":"There were no patients who achieved CR or PR. The confidence interval could not be estimated.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"There were no patients who achieved CR or PR. The confidence interval could not be estimated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Measured by RECIST v1.1 and tumor markers (AFP and BhCG). CR - disappearance of all target lesions and normalization of serum tumor markers for at least 4 weeks. When only evidence of disease is elevated serum tumor markers, then values must fall below the upper limit of normal for the assay and remain at that level for at least 4 weeks. PR - at least a 30% decrease in the sum of the diameters of target lesions compared to the baseline sum diameters for at least 2 measurements 1 month apart with the serum markers as stable/decreasing. When only evidence of disease is elevated serum tumor markers, then values must fall \\>=90% below baseline pretreatment levels for BhCG or 50% decrease below baseline pretreatment levels for AFP and persist for 6 weeks. If both tumor markers are elevated and one falls below 90% the other should fall at least below 50% of baseline pretreatment levels.The percent of patients with objective response and its 95% exact confidence interval will be provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort.","id":"OG000","title":"CD30 Negative/Unknown"},{"description":"Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort.","id":"OG001","title":"CD30 Positive"}],"paramType":"NUMBER","populationDescription":"All patients who received at least one dose of study medication and at least one evaluable assessment after treatment.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Objective Response (Percent of Patients With Complete Response or Partial Response)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}